High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

Patients were enrolled from July 2013 to December 2020 (final follow-up on January 18, 2023).

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

The D-Lay MS trial was a parallel, double-blind, randomized placebo-controlled clinical trial in 36 MS centers in France.

What Was Measured

The subject headings attached to it are Cholecalciferol, Magnetic Resonance Imaging, Multiple Sclerosis, Vitamin D Deficiency, Vitamins, Pulse Therapy, Drug and Methylprednisolone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with multiple sclerosis.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (JAMA), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.